Vesilute is strictly for laboratory research and is commonly employed in the following investigational areas:

Urological Dysfunction and Overactive Bladder

Research models utilize Vesilute (Vezusten) to evaluate its efficacy in the management of overactive bladder syndrome (OAB). Investigations focus on the peptide’s effects on detrusor overactivity, quantifying changes in urodynamic maximum cystometric capacity, daily urination frequency, and urge incontinence episodes to assess pathogenetic treatment approaches.

Ocular Tissue Cultivation and Regeneration

Experimental protocols employ this peptide bioregulator to characterize its influence on the sclera. Studies assess the application of the peptide incorporated into albumin-based cryogels during the model cultivation of a posterior eye segment, measuring its regulatory effects on ocular tissue integrity.

Neurological and Muscular Endurance Potential

In broader physiological research, dipeptides like Vesilute are used to study their diagnostic and therapeutic potential in neurological diseases. Additionally, related peptide extracts are investigated for their capacity to enhance muscle strength and exercise endurance in murine models.

Pathway / Mechanistic Context

The primary mechanism of action for Vesilute in research settings involves its function as a short peptide bioregulator, modulating cellular pathways associated with tissue-specific homeostasis and regeneration in the bladder and related systems.

• Detrusor Regulation: Interacts with the bladder wall and neural pathways to mitigate bacterial detrusor overactivity and increase cystometric capacity.
• Tissue Cultivation Support: Modulates cellular activity in scleral tissues, providing regulatory support when incorporated into cryogel delivery systems.
• Systemic Bioregulation: Influences broader neuromuscular and metabolic pathways, potentially offering therapeutic profiles in neurological and muscular endurance contexts.

Preclinical Research Summary

Published preclinical literature documents investigations of Vesilute (Vezusten) across various experimental models focusing on urological, ocular, and muscular applications.

• In urological studies, administration of the peptide regulator Vezusten demonstrated a statistically significant improvement in subjective symptoms of overactive bladder, increasing urodynamic maximum cystometric capacity and decreasing urination frequency.
• Research on ocular models indicates that protein-peptide bioregulators isolated from bovine sclera influence tissue integrity during the cultivation of the posterior eye segment.
• Investigations highlight the diagnostic and therapeutic potential of dipeptides in cerebrospinal fluid and plasma for neurological diseases.
• Broader peptide studies demonstrate the potential for functional enhancements, such as increased muscle strength and exercise endurance in mice.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• G. V. Kovalev, I. A. Labetov, R. R. Shakirova, and D. D. Shkarupa, “The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation,” Rostov State Medical University, Sep. 2024. doi: 10.21886/2308-6424-2024-12-4-50-56. Available: https://doi.org/10.21886/2308-6424-2024-12-4-50-56
• O. V. Yamskova, M. S. Krasnov, E. V. Sidorsky, and V. I. Lozinsky, “Influence of protein-peptide bioregulator isolated from bovine sclera and incorporated into an albumin-based cryogel on the sclera in a model cultivation of a posterior eye segment,” V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs, Jul. 2023. doi: 10.15825/1995-1191-2023-2-118-128. Available: https://doi.org/10.15825/1995-1191-2023-2-118-128
• K. Küper et al., “Dipeptides in CSF and plasma: diagnostic and therapeutic potential in neurological diseases,” Springer Science and Business Media LLC, Dec. 2024. doi: 10.1007/s00726-024-03434-1. Available: https://doi.org/10.1007/s00726-024-03434-1
• Y.-F. Kao et al., “Development of functional foods from grouper fish-bone residues to enhance muscle strength and exercise endurance in mice,” Frontiers Media SA, Dec. 2024. doi: 10.3389/fsufs.2024.1483028. Available: https://doi.org/10.3389/fsufs.2024.1483028

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.